Gremlin promotes vascular smooth muscle cell proliferation and migration

Journal of Molecular and Cellular Cardiology

Volumn 44, Issue 2, 2008, Pages 370-379

  Maciel, Thiago T ^a,b   Melo, Rosilene S ^a   Schor, Nestor ^a   Campos, Alexandre H ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Albert Einstein Research and Education Institute   (Brazil)

Author keywords

Bone morphogenetic proteins; Gremlin; Proliferation; Restenosis; Vascular smooth muscle cell

Indexed keywords

ANGIOTENSIN II; BONE MORPHOGENETIC PROTEIN; GREMLIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN INHIBITOR; PROTEIN P27; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; INTIMA; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA; DOWN-REGULATION; GENE SILENCING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TUNICA INTIMA;

RATTUS;

EID: 39149099992     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2007.10.021     Document Type: Article

References (42)

1. Schwartz S.M., deBlois D., and O'Brien E.R. The intima. Soil for atherosclerosis and restenosis. Circ Res 77 (1995) 445-465
2. Newby A.C., and Zaltsman A.B. Molecular mechanisms in intimal hyperplasia. J Pathol 190 (2000) 300-309
3. Schmidt-Ott K.M., Kagiyama S., and Phillips M.I. The multiple actions of angiotensin II in atherosclerosis. Regul Pept 93 (2000) 65-77
4. Kaschina E., and Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 12 (2003) 70-88
5. Raines E.W. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15 (2004) 237-254
6. Nakaoka T., Gonda K., Ogita T., Otawara-Hamamoto Y., Okabe F., Kira Y., et al. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest 100 (1997) 2824-2832
7. Wong G.A., Tang V., El-Sabeawy F., and Weiss R.H. BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1. Am J Physiol Endocrinol Metab 284 (2003) E972-E979
8. Takahashi H., Goto N., Kojima Y., Tsuda Y., Morio Y., Muramatsu M., et al. Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 290 (2006) L450-L458
9. Gazzerro E., and Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 7 (2006) 51-65
10. Li X., and Cao X. BMP signaling and skeletogenesis. Ann N Y Acad Sci 1068 (2006) 26-40
11. Chen D., Zhao M., and Mundy G.R. Bone morphogenetic proteins. Growth Factors 22 (2004) 233-241
12. Wagner T.U. Bone morphogenetic protein signaling in stem cells-one signal, many consequences. FEBS J 274 (2007) 2968-2976
13. Hruska K.A., Mathew S., and Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 97 (2005) 105-114
14. Tobin J.F., and Celeste A.J. Bone morphogenetic proteins and growth differentiation factors as drug targets in cardiovascular and metabolic disease. Drug Discov Today 11 (2006) 405-411
15. Vendrov A.E., Madamanchi N.R., Hakim Z.S., Rojas M., and Runge M.S. Thrombin and NAD(P)H oxidase-mediated regulation of CD44 and BMP4-Id pathway in VSMC, restenosis, and atherosclerosis. Circ Res 98 (2006) 1254-1263
16. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 (2003) 577-584
17. Herpin A., and Cunningham C. Cross-talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell-specific outcomes. FEBS J 274 (2007) 2977-2985
18. Balemans W., and Van Hul W. Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 250 (2002) 231-250
19. Vitt U.A., Hsu S.Y., and Hsueh A.J. Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. Mol Endocrinol 15 (2001) 681-694
20. Hsu D.R., Economides A.N., Wang X., Eimon P.M., and Harland R.M. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol Cell 1 (1998) 673-683
21. Michos O., Panman L., Vintersten K., Beier K., Zeller R., and Zuniga A. Gremlin-mediated BMP antagonism induces the epithelial-mesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development 131 (2004) 3401-3410
22. McMahon R., Murphy M., Clarkson M., Taal M., Mackenzie H.S., Godson C., et al. IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-beta1. J Biol Chem 275 (2000) 9901-9904
23. Dolan V., Murphy M., Sadlier D., Lappin D., Doran P., Godson C., et al. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am J Kidney Dis 45 (2005) 1034-1039
24. Topol L.Z., Bardot B., Zhang Q., Resau J., Huillard E., Marx M., et al. Biosynthesis, post-translation modification, and functional characterization of Drm/gremlin. J Biol Chem 275 (2000) 8785-8793
25. Morishita R., Gibbons G.H., Ellison K.E., Nakajima M., Zhang L., Kaneda Y., et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A 90 (1993) 8474-8478
26. Lehr H.A., Mankoff D.A., Corwin D., Santeusanio G., and Gown A.M. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 45 (1997) 1559-1565
27. Dorai H., Vukicevic S., and Sampath T.K. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 184 (2000) 37-45
28. ten Dijke P., Korchynskyi O., Valdimarsdottir G., and Goumans M.J. Controlling cell fate by bone morphogenetic protein receptors. Mol Cell Endocrinol 211 (2003) 105-113
29. Schwartz S.M. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 100 (1997) S87-S89
30. Prescott M.F., Webb R.L., and Reidy M.A. Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol 139 (1991) 1291-1296
31. Owens G.K., Geisterfer A.A., Yang Y.W., and Komoriya A. Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol 107 (1988) 771-780
32. Franzen A., and Heldin N.-E. BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21CIP1 and p27KIP1. Biochem Biophys Res Commun 285 (2001) 773-781
33. Tomari K., Kumagai T., Shimizu T., and Takeda K. Bone morphogenetic protein-2 induces hypophosphorylation of Rb protein and repression of E2F in androgen-treated LNCaP human prostate cancer cells. Int J Mol Med 15 (2005) 253-258
34. Namkoong H., Shin S.M., Kim H.K., Ha S.A., Cho G.W., Hur S.Y., et al. The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer 6 (2006) 74
35. Sneddon J.B., Zhen H.H., Montgomery K., van de Rijn M., Tward A.D., West R., et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A 103 (2006) 14842-14847
36. Chen B., Blair D.G., Plisov S., Vasiliev G., Perantoni A.O., Chen Q., et al. Cutting edge: bone morphogenetic protein antagonists Drm/gremlin and Dan interact with slits and act as negative regulators of monocyte chemotaxis. J Immunol 173 (20045) 914-5917
37. Liu D., Hou J., Hu X., Wang X., Xiao Y., Mou Y., et al. Neuronal chemorepellent slit2 inhibits vascular smooth muscle cell migration by suppressing small GTPase Rac1 activation. Circ Res 98 (2006) 480-489
38. Stabile H., Mitola S., Moroni E., Belleri M., Nicoli S., Coltrini D., et al. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood 109 (2007) 1834-1840
39. Chen B., Athanasiou M., Gu Q., and Blair D.G. Drm/gremlin transcriptionally activates p21(Cip1) via a novel mechanism and inhibits neoplastic transformation. Biochem Biophys Res Commun 295 (2002) 1135-1141
40. Wilensky R.L. Angiotensin-receptor blockers: revival of the systemic prevention of restenosis?. Cardiovasc Drugs Ther 17 (2003) 63-73
41. Serruys P.W., Heyndrickx G.R., Patel J., Cummins P.A., Kleijne J.A., and Clowes A.W. Effect of an anti-PDGF-beta-receptor-blocking antibody on restenosis in patients undergoing elective stent placement. Int J Cardiovasc Intervent 5 (2003) 214-222
42. Hsieh P.C., Kenagy R.D., Mulvihill E.R., Jeanette J.P., Wang X., Chang C.M., et al. Bone morphogenetic protein 4: potential regulator of shear stress-induced graft neointimal atrophy. J Vasc Surg 43 (2006) 150-158